AAAAAA

   
Results: 1-7 |
Results: 7

Authors: MEHL B SANTELL JP
Citation: B. Mehl et Jp. Santell, PROJECTING FUTURE DRUG EXPENDITURES - 1998, American journal of health-system pharmacy, 55(2), 1998, pp. 127-136

Authors: VONPAWEL J GATZEMEIER U MEHL B EDLER L BAUMGART J DRINGS P
Citation: J. Vonpawel et al., CLINICAL-PHASE-II TRIAL OF TREOSULFAN IN PATIENTS WITH NONRESECTABLE NON-SMALL-CELL LUNG-CANCER, Onkologie, 21(4), 1998, pp. 316-319

Authors: MEHL B SANTELL JP
Citation: B. Mehl et Jp. Santell, PROJECTING FUTURE DRUG EXPENDITURES - 1997, American journal of health-system pharmacy, 54(2), 1997, pp. 153-161

Authors: PROFETA LM BRADBURY K MEHL B
Citation: Lm. Profeta et al., PHARMACOKINETIC CONSIDERATIONS IN PHENYTOIN PHARMACOTHERAPY - PREVENTING OVERDOSES AND UNDERDOSES, The Mount Sinai journal of medicine, 62(4), 1995, pp. 312-314

Authors: CALIENDO G BRADBURY K MEHL B
Citation: G. Caliendo et al., TICLOPIDINE, BLEEDING, AND SURGERY, The Mount Sinai journal of medicine, 61(4), 1994, pp. 372-373

Authors: BRADBURY K WANG J HASKINS G MEHL B
Citation: K. Bradbury et al., PREVENTION OF MEDICATION ERRORS - DEVELOPING A CONTINUOUS-QUALITY-IMPROVEMENT APPROACH, The Mount Sinai journal of medicine, 60(5), 1993, pp. 379-386

Authors: MEHL B
Citation: B. Mehl, DEFINING EXCELLENCE, American journal of hospital pharmacy, 50(5), 1993, pp. 921-928
Risultati: 1-7 |